X

Drug Profile

BT 0267

Alternative Names: BT 267; BT-0267

Latest Information Update: 26 Mar 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Brenig Therapeutics
Class Antiparkinsonians; Small molecules
Mechanism of Action LRRK2 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Parkinson's disease

Most Recent Events

18 Mar 2024 Brenig Therapeutics plans a clinical trial for Parkinson's disease by the end of 2024
04 Dec 2023 Preclinical trials in Parkinson's disease in USA (unspecified route), prior to December 2023
04 Dec 2023 Pharmacokinetics and adverse events data from a preclinical trial in Parkinson's disease released by Brenig Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com